<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956835</url>
  </required_header>
  <id_info>
    <org_study_id>CINS</org_study_id>
    <nct_id>NCT04956835</nct_id>
  </id_info>
  <brief_title>The Implementation of the Classification of Intraoperative Adverse Events (ClassIntra) for Neurosurgical Procedures</brief_title>
  <official_title>The Implementation of the Classification of Intraoperative Adverse Events (ClassIntra) for Neurosurgical Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the planned study, the ClassIntra score will be assessed after all neurosurgical&#xD;
      procedures in the upcoming 6 months and correlated with all pre- and postoperative data.&#xD;
      Afterwards, the conclusion will be made, if the ClassIntra score could predict the&#xD;
      postoperative course of the patients regarding their neurological and general condition.&#xD;
      Furthermore, analyses will be made to develop novel postoperative routines adjusted to the&#xD;
      individual ClassIntra score of the patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgeons strive for the best possible outcome of their surgeries with the greatest possible&#xD;
      chance for recovery of the patients. Therefore, monitoring and quality improvement is&#xD;
      increasingly important in surgery. As there are well-defined scores and classifications to&#xD;
      describe the postoperative course regarding morbidity, mortality and neurological status, no&#xD;
      validated classification for intraoperative quality exists by now. However, Dell-Kuster et&#xD;
      al. introduced a novel classification for assessing all intraoperative adverse events:&#xD;
      ClassIntra. This classification was developed in a Delphi consensus containing international,&#xD;
      interdisciplinary, and validated in a multicentre cohort study across all surgical&#xD;
      disciplines. The classification defines intraoperative adverse events as any deviation from&#xD;
      the ideal intraoperative course occurring between skin incision and skin closure and contains&#xD;
      any event related to surgery and anaesthesia. Depending on the kind of adverse event, the&#xD;
      ClassIntra score ranges from 0 (no event) to 5 (intraoperative death). A prospective study&#xD;
      with a main focus on neurosurgery covering the whole spectrum of elective and emergency&#xD;
      procedures is needed. Hereby, the outcome parameters need to be defined specific for&#xD;
      neurosurgical procedures including a preoperative and postoperative neurological status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complications according to Clavien-Dindo classification</measure>
    <time_frame>within two weeks after surgery</time_frame>
    <description>Grade 0 to V (0 no complication, V death)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehensive Complication Index</measure>
    <time_frame>within two weeks after surgery</time_frame>
    <description>Based on Clavien-Dindo classification with a scale from 0 to 100 (0 no complication, 100 death)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological status</measure>
    <time_frame>within two weeks after surgery</time_frame>
    <description>classified to NANO scale, NIHSS, modified Rankin Scale, Glasgow Outcome Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological outcome (NANO scale)</measure>
    <time_frame>within two weeks after surgery</time_frame>
    <description>according to neurological assessment in neuro-oncology (NANO) with a scale from 0 to 23 (0 no neurological deficit, 23 multiple neurological deficits)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological outcome (NIHSS)</measure>
    <time_frame>within two weeks after surgery</time_frame>
    <description>according to National Institutes of Health Stroke Scale (0 no stroke symptoms 1-4 minor stroke 5-15 moderate stroke 16-20 moderate to severe stroke 21-42 severe stroke)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological outcome (mRS)</measure>
    <time_frame>within two weeks after surgery</time_frame>
    <description>according to modified Rankin Scale with a scale from 0 to 6 (0 no symptoms, 6 dead)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>within two weeks after surgery</time_frame>
    <description>Death of the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>within two weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>within two weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rate</measure>
    <time_frame>within 90 days after surgery</time_frame>
    <description>Readmission to hospital after discharge</description>
  </secondary_outcome>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Neurological Morbidity</condition>
  <condition>Surgical Complication</condition>
  <condition>Anesthesia Morbidity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing surgery at a neurosurgical department either elective or emergency&#xD;
        surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing surgery at a neurosurgical department&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Drexler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Drexler, MD</last_name>
    <phone>+4915222816461</phone>
    <email>r.drexler@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lasse Dührsen, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <state>Hambrug</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Drexler, MD</last_name>
      <email>r.drexler@uke.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Dell-Kuster S, Gomes NV, Gawria L, Aghlmandi S, Aduse-Poku M, Bissett I, Blanc C, Brandt C, Ten Broek RB, Bruppacher HR, Clancy C, Delrio P, Espin E, Galanos-Demiris K, Gecim IE, Ghaffari S, Gié O, Goebel B, Hahnloser D, Herbst F, Orestis I, Joller S, Kang S, Martín R, Mayr J, Meier S, Murugesan J, Nally D, Ozcelik M, Pace U, Passeri M, Rabanser S, Ranter B, Rega D, Ridgway PF, Rosman C, Schmid R, Schumacher P, Solis-Pena A, Villarino L, Vrochides D, Engel A, O'Grady G, Loveday B, Steiner LA, Van Goor H, Bucher HC, Clavien PA, Kirchhoff P, Rosenthal R. Prospective validation of classification of intraoperative adverse events (ClassIntra): international, multicentre cohort study. BMJ. 2020 Aug 25;370:m2917. doi: 10.1136/bmj.m2917.</citation>
    <PMID>32843333</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Richard Drexler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

